Hepatitis C management at federally qualified health centers proves cost-effective

July 08, 2020

BOSTON- New research from Boston Medical Center shows that routine Hepatitis C (HCV) testing at federally qualified health centers (FQHC) improves diagnosis rates and health outcomes for people with HCV infections in the United States, and is cost-effective. The formerly recommended targeted testing approach was shown to provide worse outcomes at a higher cost when compared to routine testing.

Published in the American Journal of Medicine, results show that these health care facilities can provide opportunities to enhance HCV testing and treatment, where care is typically provided to an underserved and diverse patient population with a high proportion of both injection drug use and HCV. This comes at a time when there has been an increase in HCV infections due to the opioid epidemic, and as recent data show that the United States is not on the list of high-income nations expected to achieve the World Health Organization's goal of eliminating HCV by 2030.

"Routine testing at federally qualified health centers is shown to provide better health outcomes and reduced financial burden compared to targeted testing," said Sabrina Assoumou, MD, MPH, an infectious diseases physician at Boston Medical Center and assistant professor of medicine at Boston University School of Medicine. "Federally qualified health centers can serve as venues to enhance testing and treatment, reducing the impact of HCV in the country."

Counselor-initiated routine rapid-testing with follow-up RNA testing identified 75 percent of cases at the FQHC compared to only seven percent identified by risk-based targeted testing by a clinician. By having a dedicated counselor initiate and perform testing, there was an increase in the percentage of cases identified by 41 percent compared to alternative approaches where clinicians were offering testing. In addition, targeted testing missed patients with no identified substance use. For example, risk-based laboratory-based targeted testing by a clinician only identified seven percent of HCV infections in the first month of the intervention whereas clinician-initiated phlebotomist-performed routine laboratory-based testing identified 25 percent of infections.

The Centers for Disease Control and Prevention (CDC) and the US Preventive Services Task Force (USPSTF) have recently updated recommendations to include one-time HCV testing screening for adults 18 years and older. This new research provides data on the cost-effectiveness of alternative testing approaches to expand testing and treatment in high prevalence clinical settings, specifically evaluating the relative costs and comparative outcomes of various implementation models for HCV testing. Using simulation modeling, routine rapid HCV testing is shown to be cost-effective when compared to risk-based laboratory testing at US FQHC. Compared to risk-based laboratory testing, routine rapid testing performed by a counselor identified 68 percent more cases in the first month and resulted in a 22 percent reduction in liver deaths among patients with liver cirrhosis. This intensive approach to testing in FQHCs shifts the timing of cure to early disease stage, preventing liver-related morbidity and reducing HCV-attributable deaths, even when there is substantial ongoing hepatitis C testing at venues elsewhere.

Individual-level data was used from 57 FQHCs to model 9 strategies, including permutations of HCV antibody testing modality, person initiating testing and testing approach. The outcomes included life expectancy, quality adjusted life years (QALY), hepatitis C cases identified, treated and cured, and incremental cost-effectiveness ratios (ICERs).  
Funding for this study was provided by the U.S. Centers for Disease Control and Prevention (CDC), National Center for HIV, Viral Hepatitis, STD, and TB Prevention Epidemiologic and Economic Modeling Agreement (NU38PS004644). Support was also obtained from the National Institute of Drug Abuse (K23 DA044085, R01 DA046527, P30 DA040500).

About Boston Medical Center

Boston Medical Center is a private, not-for-profit, 514-bed, academic medical center that is the primary teaching affiliate of Boston University School of Medicine. It is the largest and busiest provider of trauma and emergency services in New England. Boston Medical Center offers specialized care for complex health problems and is a leading research institution, receiving more than $97 million in sponsored research funding in fiscal year 2018. It is the 15th largest funding recipient in the U.S. from the National Institutes of Health among independent hospitals. In 1997, BMC founded Boston Medical Center Health Plan, Inc., now one of the top ranked Medicaid MCOs in the country, as a non-profit managed care organization. Boston Medical Center and Boston University School of Medicine are partners in Boston HealthNet - 14 community health centers focused on providing exceptional health care to residents of Boston. For more information, please visit http://www.bmc.org.

Boston Medical Center

Related Hepatitis Articles from Brightsurf:

Busting Up the Infection Cycle of Hepatitis B
Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the ''spiky ball'' that encloses its genetic blueprint.

Liver cancer: Awareness of hepatitis D must be raised
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma.

Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.

Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.

Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.

How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.

New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.

High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.

Read More: Hepatitis News and Hepatitis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.